Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Halts The TIDE Of New Avandia Patients; Informed Consent Changes Loom

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency's partial clinical hold prevents new subjects from enrolling in GlaxoSmithKline's postmarketing safety study of rosiglitazone and suggests informed consent process for current subjects be revised to reflect advisory committee deliberations on the drug's safety.
Advertisement

Related Content

FDA Keeps Avandia On The Market But Looks To RECORD For More Clarity On CV Risk
FDA Keeps Avandia On The Market But Looks To RECORD For More Clarity On CV Risk
Avandia, Actos Comparative Safety Evaluation "Not Novel," FDA Says
Avandia, Actos Comparative Safety Evaluation "Not Novel," FDA Says
Avandia Can Be Saved With New Warnings and REMS, Advisory Cmte. Says
Avandia Can Be Saved With New Warnings and REMS, Advisory Cmte. Says
Avandia's TIDE May Come In Smaller
IoM Report On Postmarketing Study Ethics Could Drive Broad Overhaul Of Informed Consent

Topics

Advertisement
UsernamePublicRestriction

Register

PS070937

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel